ALLERO THERAPEUTICS
Allero Therapeutics is a biopharmaceutical company that develops next generation immunotherapies for immune mediated disorders. Based on research by the founders and their collaborators the team has identified a novel specific immunotherapy approach based on antigen-specific tolerance induction. The approach defines a platform technology which is broadly applicable to a range of clinical indications with profound unmet medical need.
ALLERO THERAPEUTICS
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2016-01-01
Address:
Rotterdam, Zuid-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.allerotherapeutics.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
82.94 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Microsoft Exchange Online GStatic Google Static Content Wix Wix Forms
Similar Organizations
Zentera Therapeutics
Zentera Therapeutics is a biopharmaceutical company.
Current Employees Featured
Founder
Investors List
Swanbridge Capital
Swanbridge Capital investment in Seed Round - Allero Therapeutics
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Allero Therapeutics
Official Site Inspections
http://www.allerotherapeutics.com Semrush global rank: 5.64 M Semrush visits lastest month: 1.5 K
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Allero Therapeutics" on Search Engine
Allero Therapeutics - Crunchbase Company Profile
Company Type For Profit. Contact Email [email protected]. Allero Therapeutics is a biopharmaceutical company that develops next generation immunotherapies for …See details»
Allero Therapeutics Company Profile 2024: Valuation, …
The company's therapies are designed to induce long-lasting antigen-specific tolerance to develop next-generation immunotherapies for allergic and autoimmune disease patients, …See details»
Allero Therapeutics BV | LinkedIn
Allero Therapeutics is a Dutch biotech company that develops next generation immunotherapies for immune mediated disorders. Our goal is to develop novel targeted …See details»
Allero Therapeutics Expands Management Team with Two Key …
Dec 15, 2020 Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, today announced the appointment of two key members to its management …See details»
Allero: treating food-related immune diseases through an oral patch
May 17, 2021 By Lauren Martz, Senior editor. May 17, 2021 9:02 PM UTC. Allero emerged from stealth last year to develop an oral patch-based immunotherapy that could lead to …See details»
Allero Therapeutics: Breakthrough Innovation For …
Posted on December 21, 2022. Allero Therapeutics, based in Rotterdam, was founded in 2016 by Emil Pot, Federico Grego, Kees Leenhouts, and Poul Sørensen. Allero’s mission is to improve the quality of life for …See details»
Allero Therapeutics and Abbreos Join Forces to Clinically …
Nov 24, 2020 Allero Therapeutics is an immunotherapy company building a portfolio of first-in-class programs based on its proprietary Specific OroMucosal ImmunoTherapy …See details»
Company News: Allero Therapeutics and Abbreos Join Forces to …
Nov 24, 2020 Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, and Abbreos Inc., a US- based IND-stage company focused on developing …See details»
Allero Therapeutics Company Profile - Craft
Allero Therapeutics is a biopharmaceutical company that develops immunotherapies for allergic and autoimmune disease patients. Its proprietary SOMIT (Specific OroMucosal …See details»
Allero Therapeutics Receives EIC Horizon Grant to Advance …
Nov 24, 2022 Rotterdam, The Netherlands, November 24, 2022 – Allero Therapeutics BV, a Dutch oromucosal immunotherapy company, today announced that the Company …See details»
Allero Therapeutics Expands Management Team with Two Key …
Allero Therapeutics is an immunotherapy company building a portfolio of first-in-class programs based on its proprietary Specific OroMucosal ImmunoTherapy (SOMIT) …See details»
Leveraging a novel platform technology to develop a first-in-class ...
Aug 12, 2022 In this project, Allero Therapeutics will collaborate with two leading research institutes (Leiden University Medical Center from the Netherlands and the …See details»
Allero Therapeutics | EU-Startups
Nov 18, 2022 Tags. Biotechnology, Pharmaceutical, Immunotherapy. Total Funding. Between €1-€100K. Founded. 2016. Website. https://www.allerotherapeutics.com/ …See details»
☑️Allero Therapeutics — Consulting Organization from the …
Nov 7, 2022 Allero Therapeutics is a venture-backed, biopharmaceutical company that develops next generation immunotherapies for food-related immune disorders. Our goal …See details»
Allero Therapeutics - Funding, Financials, Valuation & Investors
Lead Investors 1. Investors 3. Funding. Allero Therapeutics has raised a total of. €2.6M. in funding over 3 rounds. Their latest funding was raised on Oct 21, 2021 from a Grant …See details»
ALLERO THERAPEUTICS | VentureRadar
Allero Therapeutics develops next generation immunotherapies for allergic and autoimmune disease patients, with a focus on food-related immune... ... Find out more …See details»
Allero Therapeutics Receives EIC Horizon Grant to Advance …
Nov 24, 2022 Allero Therapeutics BV, a Dutch oromucosal immunotherapy company, today announced that the Company has received a EUR 2.5 million EIC Horizon Grant …See details»
Allero Therapeutics - Crunchbase
Allero Therapeutics, Accent Therapeutics, Context Therapeutics, Saol Therapeutics, Nymox Pharmaceutical, and IntraBio are part of the biopharmaceutical industry. Accent …See details»
Q1 2024 Autolus Therapeutics PLC Earnings Call - Yahoo Finance
14 hours ago So to now summarize our results for the quarter. Cash and cash equivalents at March 31, 2024, totaled $758.5 million as compared to $239.6 million at December 31, …See details»